UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 154

Sortiert nach

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

British journal of cancer, 2019-10, Vol.121 (9), p.725-737

2019

Volltextzugriff (PDF)

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors

European journal of cancer (1990), 2020-06, Vol.132, p.122-124

2020

Volltextzugriff (PDF)

MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions

Drug resistance updates, 2019-01, Vol.42, p.1-11

2019

Volltextzugriff (PDF)

Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges

Cancers, 2024-07, Vol.16 (14), p.2610

2024

Volltextzugriff (PDF)

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

Journal of cancer research and clinical oncology, 2021-10, Vol.147 (10), p.3135-3137

2021

Volltextzugriff (PDF)

Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy

Current treatment options in oncology, 2021-11, Vol.22 (11), p.96-96, Article 96

2021

Volltextzugriff (PDF)

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review

Frontiers in oncology, 2021-04, Vol.11, p.642190

2021

Volltextzugriff (PDF)

The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios

Molecular biology reports, 2021-04, Vol.48 (4), p.3485-3494

2021

Volltextzugriff (PDF)

Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study

Clinical Medicine Insights. Oncology, 2021, Vol.15, p.11795549211043427-11795549211043427

2021

Volltextzugriff (PDF)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature

Cancers, 2021-10, Vol.13 (21), p.5403

2021

Volltextzugriff (PDF)

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs

Cells (Basel, Switzerland), 2021-06, Vol.10 (6), p.1520

2021

Volltextzugriff (PDF)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Drug design, development and therapy, 2018-01, Vol.12, p.2857-2873

2018

Volltextzugriff (PDF)

Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review

Clinical genitourinary cancer, 2016-08, Vol.14 (4), p.277-283

2016

Volltextzugriff (PDF)

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

Cancer treatment and research communications, 2020, Vol.22, p.100161-100161, Article 100161

2020

Volltextzugriff (PDF)

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

Drug resistance updates, 2019-09, Vol.46, p.100644-100644, Article 100644

2019

Volltextzugriff (PDF)

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall

Cancer treatment reviews, 2018-05, Vol.66, p.82-94

2018

Volltextzugriff (PDF)

Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC

Journal of thoracic oncology, 2024-08, Vol.19 (8), p.1128-1132

2024

Volltextzugriff (PDF)

Small cell lung cancer: Novel treatments beyond immunotherapy

Seminars in cancer biology, 2022-11, Vol.86, p.376-385

2022

Volltextzugriff (PDF)

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Clinical lung cancer, 2021-09, Vol.22 (5), p.473-477

2021

Volltextzugriff (PDF)

Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?

Critical reviews in oncology/hematology, 2021-10, Vol.166, p.103454-103454, Article 103454

2021

Volltextzugriff (PDF)

The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer

Anticancer research, 2020-09, Vol.40 (9), p.4807-4818

2020

Volltextzugriff (PDF)

Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Critical reviews in oncology/hematology, 2021-03, Vol.159, p.103241-103241, Article 103241

2021

Volltextzugriff (PDF)

Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression

European journal of cancer (1990), 2021-11, Vol.157, p.520-522

2021

Volltextzugriff (PDF)

Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?

Expert opinion on pharmacotherapy, 2020-07, Vol.21 (11), p.1287-1298

2020

Volltextzugriff (PDF)

Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib

Immunotherapy, 2022-11, Vol.14 (16), p.1297-1305

2022

Volltextzugriff (PDF)

1 – 25 von 154

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(138)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(115)
Life Sciences & Biomedicine
(108)
Humans
(67)
Oncology
(47)
Male
(30)
Female
(27)
Middle Aged
(27)
Aged
(24)
Adult
(22)
Retrospective Studies
(19)
Lung Cancer
(17)
Medicine
(15)
Medicine & Public Health
(15)
Patients
(14)
Immunotherapy
(13)
Cancer Therapies
(12)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(12)
Chemotherapy
(12)
Lung Neoplasms - Drug Therapy
(12)
Metastasis
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors

MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions

Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review

The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios

Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review

Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall

Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC

Small cell lung cancer: Novel treatments beyond immunotherapy

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial

Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?

The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer

Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression

Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?

Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib

Suchergebnisse filtern